Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Metabolic Diseases Header 4

MASH/MASLD Resource Toolkit

 

  1. What’s in a name? NAFLD is now MASFLD
  2. The Fatty Liver Foundation, FIB-4 Index. Accessed October 3, 2024.
  3. Fibrosis-4 (FIB-4) Index for Liver Fibrosis - “When to Use”, “Why To Use,” and “Pearls and Pitfalls”
  4. Global incidence and prevalence of nonalcoholic fatty liver disease
  5. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
  6. Mechanisms of NAFLD development and therapeutic strategies
  7. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
  8. Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
  9. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
  10. Nonalcoholic steatohepatitisdiagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey
  11. MASLD requires multidisciplinary care to ‘improve global metabolic, liver health’
  12. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
  13. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
  14. Sampling variability of liver biopsy in nonalcoholic fatty liver disease (PDF: Depending on your browser settings, file will either open in new window or download to your computer)
  15. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology
  16. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
  17. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
  18. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease

 

Click here to take the survey and receive your certificate.